Abstract: The present invention has an object of the present invention to provide a polyvinyl acetal resin for heat-developable photosensitive materials as well as a heat-developable photosensitive material while solving such problems as coating solution pot life, coloration of heat-developable photosensitive material, fog, poor gradation, insufficient sensitivity and poor undeveloped film storability and making it possible for the materials to acquire good image characteristics. The present invention is constituted of a polyvinyl acetal resin for heat-developable photosensitive materials which is a polyvinyl acetal resin synthesized by the acetalization reaction between a polyvinyl alcohol and an aldehyde and which comprises having a degree of polymerization of 200 to 3,000, a residual acetyl group content of 0 to 25 mole percent and a residual hydroxyl group content of 17 to 35 mole percent, as calculated while regarding one acetal group as two acetalized hydroxyl groups, a water content of not more than 2.

Abstract: A water-based emulsion for vibration damper is provided for the formation of an excellent vibration damper. In an aspect, the emulsion for vibration damper contains a particle including a core part formed of an acrylic copolymer (A) and a shell part formed of an acrylic copolymer (B) which covers the core part, the glass transition point of the acrylic copolymer (B) being not lower than ?9° C., and the difference between the glass transition point of the acrylic copolymer (B) and the glass transition point of the acrylic copolymer (A) being not less than 20° C.

Abstract: This invention relates High Density Polyethylene (HDPE) films having improved barrier properties. More particularly, the invention relates to HDPE films containing hydrocarbon resins having improved moisture barrier. The invention also relates to masterbatches for use in producing High Density Polyethylene films having improved barrier properties.

Abstract: The invention is the manipulation of the zinc oxide content and sulfur content of nitrile butadiene rubbers and selected vulcanization conditions that can be achieved economically with common production facilities. The manipulation of these components affects the relaxation property of gloves formed by this material. Produced are gloves that have a relaxation property, higher than 50%, and a low modulus (approximately 3 Mpa). The glove maintains decent ultimate tensile strength (>20 Mpa) and elongation (>500%). The glove is produced by a vulcanization process, which lasts from 5 to 60 minutes at temperatures ranging from 300° F. to 400° F. The tensile strength and elongation are well above the ASTM requirements for medical gloves. The current ASTM requirements are ASTM D412-92. Thanks to sufficient vulcanization, the films produced provide satisfactory protection from viral penetration. The tearing strength is also better because of the lower modulus.

Abstract: Medical devices with polymer coatings designed to control the release of angiotensin-(1-7) receptor agonists from medical devices are disclosed. The present application also discloses providing vascular stents with angiotensin-(1-7) receptor agonist-containing controlled-release coatings. Methods for treating or inhibiting post-stent implantation restenosis as well as improving vascular endothelial function in patients are also provided.

Abstract: The hydrogenated vinyl-polybutadienes according to the present invention have degrees of hydrogenation of from 20 to 100%, Mooney viscosities in the range of from 10 to 150 Mooney units (ML 1+4/100° C.), glass transition temperatures (Tg) of ??57° C. and enthalpies of fusion (?H) of ?30 J/g and having a microstructure with a) from 0 to 44 wt. % 1,2-vinyl-butadiene units of the formula b) from 20 to 64 wt. % 1,2-butylene units of the formula c) from 0 to 60 wt. % 1,4-butenylene units of the formula CH2—CH?CH—CH2 and d) from 0 to 60 wt. % 1,4-butylene units of the formula CH2—CH2—CH2—CH2 are outstandingly suitable for the production of rubber molded bodies of any kind, especially for the production of industrial rubber articles and of tires and tire components. The rubber molded bodies produced from the hydrogenated vinyl-polybutadienes according to the present invention have good resistance to ageing and good elasticity at low temperatures.

Abstract: An acrylic rubber composition comprising a carboxyl group-containing acrylic rubber (A) comprising 0.1 to 30% by weight of structural units derived from methacrylonitrile, and a polyamine crosslinking agent (B) and a monoamine compound (C); wherein the amount of each of the crosslinking agents (B) and the monoamine compound (C) is in the range of 0.05 to 20 parts by weight based on 100 parts by weight of the acrylic rubber (A). This acrylic rubber composition is free from sticking to a metal at kneading and exhibits good resistance to scorch during being processed, and gives a crosslinked product having good heat resistance, good cold resistance and good resistance to deteriorated oil.

Abstract: A process for manufacture of a dendritic polyether comprising a core, derived from a compound having two or more hydroxyl groups, and at least one branching generation being built up from at least one hydroxyoxetane having one oxetane group and at least one hydroxyl group is disclosed. The process comprises ring opening addition to said core and ring opening polymerization of said hydroxyoxetane. A mixture of the core compound and at least one cationic initiator is prepared and said hydroxyoxetane is fed to said mixture at a rate resulting in and/or maintaining a reaction temperature below onset at thermal degradation and in an amount resulting in at least one branching generation. The initiator is present in an amount of 0.1–0.5% by weight calculated on said core and said oxetane, preferably in an amount giving a ratio hydroxyl groups to initiator of between 1:0.01 and 1:0.05. Yielded dendritic polyether is sebsequently neutralised by addition of at least one alkaline compound and optionally purified.

Abstract: A process for producing low molecular weight, granular polytetrafluoroethylene or modified polytetrafluoroethylene by suspension polymerization of pressurized tetrafluoroethylene in an agitated reaction vessel. The polymerization is conducted in aqueous medium in the presence of a free radical initiator, and a telogen. The reaction vessel is agitated during polymerization sufficiently to coagulate the polytetrafluoroethylene or modified polytetrafluoroethylene. Low molecular weight granular polytetrafluoroethylene or modified polytetrafluoroethylene having a melt viscosity of less than about 1×106 Pa·S powder is isolated directly from the reaction vessel.

Abstract: A catalyst for polymerizing vinyl compounds or ?-olefins according to the present invention includes (A) a transition metal complex, (B) a clay, clay mineral or ion-exchangeable layered compound, modified with at least one organic compound selected from the group consisting of quaternary ammonium salts, amine compounds, and adducts of amine and Brönsted acid, and (C) at least one aluminoxy compound. The transition metal in (A) is selected from Groups 4 to 10 or Groups 8 to 10 of the Periodic Table for catalysts for vinyl compounds or ?-olefins, respectively. The aluminoxy compound is represented by the general Formula wherein a plurality of R groups are each independently C1-10 hydrocarbon group and at least one of the R groups is a hydrocarbon group having 2 or more carbon atoms; and z is an integer of 2 or more for catalyst for vinyl compounds and 2 to 4 for catalysts for ?-olefins.

Abstract: A fluorine-containing polymer which is an active component of a surface treatment agent having excellent water- and oil-repellency is constituted by a fluorine-containing polyether monomer of the formula: wherein Rf is a perfluoroalkyl group having 1 to 18 carbon atoms, R is hydrogen or a methyl group, A1 is a divalent linear or branched aliphatic group having 1 to 20 carbon atoms, A2 is a direct bond, or a divalent linear or branched aliphatic group having 1 to 10 carbon atoms which may have an ether linkage, X is a trivalent linear or branched aliphatic group having 2 to 5 carbon atoms, and n is from 1 to 100.

Abstract: Provided are novel reactive functionalized fumaric- and itaconic-containing prepolymers and compositions comprising the prepolymers used in the manufacture of medical devices. The prepolymers can be used to provide surface modified contact lenses formed from one or more fumaric- or itaconic-containing prepolymers having reactive functionality that is complimentary to reactive, hydrophilic polymers.

Abstract: The curable composition of the present invention contains (A1) a silyl-containing ethylene/?-olefin/non-conjugated polyene random copolymer rubber which has a structural unit derived from a norbornene compound as the non-conjugated polyene with at least one specific vinyl group at the terminal and contains a specific hydrolyzable silyl group, and (B) a compound, other than the rubber (A1), having a hydroxyl group and/or a hydrolyzable group, e.g., (B1) a compound having a silanol group and/or a compound which can react with moisture to form a compound having a silanol group in the molecule. This compound improves elongation of the cured product and residual surface tackiness, and, at the same time, is high in curing speed and capable of giving the cured product of high resistance to weather. It is suitable for, e.g., adhesives, tackifiers, paints, sealants, waterproof materials, spray materials, shaping materials and casting rubber materials.

Abstract: Provided is a curable composition including (A) an addition reaction product of (a) a compound with 2 silicon atom-bonded hydrogen atoms within each molecule, having a general formula (1): wherein, A is a bivalent group represented by a formula (2): (wherein, R? represents an unsubstituted or substituted monovalent hydrocarbon group of 1 to 12 carbon atoms, or an alkoxy group of 1 to 6 carbon atoms, and n represents an integer from 0 to 100), or a group having a structural formula (3): and each R represents an unsubstituted or substituted monovalent hydrocarbon group of 1 to 12 carbon atoms, or an alkoxy group of 1 to 6 carbon atoms, and (b) a polycyclic hydrocarbon with 2 addition reactive carbon-carbon double bonds within each molecule, said addition reaction product containing at least two addition reactive carbon-carbon double bonds in each molecule, (B) a compound with at least 3 silicon atom-bonded hydrogen atoms within each molecule, and (C) a hydrosilylation reaction catalyst.

Abstract: A process for preparing high-functionality, highly branched polyureas comprises the steps a) reaction of an at least bifunctional capped diisocyanate or polyisocyanate with at least one at least bifunctional primary and/or secondary amine with elimination of the capping agent, b) intramolecular reaction of the reaction product from step a) to form a high-functionality, highly branched polyurea.

Abstract: A polymeric material which exhibits an optically detectable response to changes in pressure. The material includes an elastomer selected from the group of a polyurethane, a polyacrylate, and a silicone, in combination with a photochemical system. The photochemical system may be in the form of an exciplex or a fluorescence resonance energy transfer. Both photochemical systems are reversible processes. Synthesis of the elastomer and the photochemical system produce a material which forms an excited charge transfer complex when subject to an increase in pressure and a less excited charge transfer complex as pressure is lowered.

Abstract: Functionalized porous poly(aryl ether ketone) articles are prepared by reacting ketone groups in the backbone of poly(aryl ether ketone) polymer with a primary amine reagent. Preferred functional primary amines are primary aliphatic amines or substituted hydrazines containing one or more target functional groups including polar groups, such as hydroxyl groups, ˜OH, amino groups, ˜NH2, ˜NHR, ˜NRR?, and ethylene oxide groups, ˜OCH2CH2—, negatively or positively charged ionic groups, such as ˜SO3?, ˜COO?, and ˜NH4+ groups, hydrophobic groups such as siloxane or perfluorcarbone groups, and non-polar groups, such as linear or branched hydrocarbon groups. The functionalized porous poly(aryl ether ketone) article can be prepared by reacting primary amine with a pre-formed, shaped porous poly(aryl ether ketone) article or by functionalizing the surface of a non-porous precursor article that is subsequently converted into a porous article.

Abstract: A method of manufacturing a plastic container includes adding nano-sized silica particles to a saturated polyester in an amount of 20 ppm to 10% by weight during transesterification or esterification and polycondensing an aromatic dicarboxylic acid and ethylene glycol as starting materials. The silica particles have an average particle diameter of 3–100 nm. The saturated polyester is polyethyleneterephthalate.

Abstract: Isolated peptides of the Bacillus anthracis Anthrax Toxin Lethal factor Protein pX01–107, antibodies specific for the peptides and methods of stimulating the immune response of a subject to produce antibodies to the Bacillus anthracis Anthrax Toxin Lethal factor Protein pX01–107 are disclosed. Also disclosed are isolated peptides of the Small Pox Virus Surface Antigen S Precursor Protein, antibodies specific for the peptides and methods of stimulating the immune response of a subject to produce antibodies to the Small Pox Virus Surface Antigen S Precursor Protein.

Abstract: An object of the invention is to provide an antimicrobial peptide having an amino acid sequence which is different from a peptide existing and functioning as an antimicrobial peptide in the natural world and is not based on the conventional developmental approach for an antimicrobial peptide-containing antimicrobial agent, and a polynucleotide coding for said peptide. Another object is to provide an antimicrobial agent which contains such an antimicrobial peptide. Namely, an antimicrobial peptide represented by a general formula (1) (Xa)n-S??(1) wherein Xa of the formula (1) is a hydrophilic amino acid residue, n is an integer of from 1 to 6, two or more of the Xa may be the same or different from one another, S is a peptide represented by hydrophobic amino acid part-basic amino acid part-bridge part-basic amino acid part-hydrophobic amino acid part, and amino acid residue of the bridge part is selected from the group consisting of hydrophobic amino acids and neutral amino acids.

Abstract: Compounds that modulate the function of anti-apoptotic proteins such as Bcl-2 and Bcl-XL are identified. These compounds have the ability to convert the activity of Bcl-2-family member proteins from anti-apoptotic to pro-apoptotic. Methods for inducing apoptosis are described, together with methods for identifying molecules that induce apoptosis through interaction with Bcl-2-family members.

Abstract: The present invention discloses fusion proteins comprising transferrin, lactoferrin or melanotransferrin fused to glucagon-like peptide 1 (GLP-1). In one embodiment of the invention, the fusion protein displays increased serum half-life as compared to a GLP-1 peptide in an unfused state. The invention includes a pharmaceutical composition comprising the GLP-1 fusion protein of the invention and a carrier. The fusion protein of the invention can be administered to a subject for treatment of diseases or conditions treatable by GLP-1, including, but not limited to, diabetes, obesity, congestive heart failure and inflammatory bowel syndrome.

Abstract: A cyclic peptide with a C-terminus —OH group. Further provided are compositions and methods for treatment of sexual dysfunction in mammals, including male sexual dysfunction, such as erectile dysfunction, and female sexual dysfunction, by administration of a cyclic peptide including a C-terminus —OH group. Methods of administration include injection, oral, urethral, vaginal, nasal and mucosal administration.

Abstract: The invention provides isolated polypeptides from the venom of the scorpion P. transvaalicus. The invention also provides novel scorpion antivenom compositions derived from such polypeptides, as well as methods for isolating the polypeptides and preparing scorpion antivenom compositions. The isolated polypeptides can be used to produce pharmaceutical compositions useful for treating diseases and conditions associated with ion channel function or kinin activity.

Abstract: Peptides that have potent PLA2-inhibitory activity are disclosed. Homology searches of known PLA inhibitory molecules were used to identify and subsequently design potent peptide molecules that can induce neuroprotective as well as anti-inflammatory effect. These peptides were shown to protect against degeneration of joints in transgenic mouse model prone to arthritis. Protection from kainate-induced excitotoxic neuronal injury was also observed using these peptides. These peptides, their analogs and derivatives have potential as neuroprotective and/or anti-inflammatory agents in a clinical setting.

Abstract: The present invention relates to an improved process for the production of peptides by solid-phase synthesis. The invention also relates to agents, which are useful in solid-phase peptide synthesis.

Abstract: Disclosed are cDNAs and genomic DNAs encoding protease-activated receptor 3 (PAR3) from mouse and human, and the recombinant polypeptides expressed from such cDNAs. The recombinant receptor polypeptides, receptor fragments and analogs expressed on the surface of cells are used in methods of screening candidate compounds for their ability to act as agonists or antagonists to the effects of interaction between thrombin and PAR3. Agonists are used as therapeutics to treat wounds, thrombosis, atherosclerosis, restenosis, inflammation, and other thrombin-activated disorders. Antagonists are used as therapeutics to control blood coagulation and thereby treating heart attack and stroke. Antagonists mediate inflammatory and proliferative responses to injury as occur in normal wound healing and variety of diseases including atherosclerosis, restenosis, pulmonary inflammation (ARDS) and glomerulosclerosis.

Abstract: Disclosed are (1) osteogenic devices comprising a matrix containing substantially pure natural-sourced mammalian osteogenic protein; (2) DNA and amino acid sequences for novel polypeptide chains useful as subunits of dimeric osteogenic proteins; (3) vectors carrying sequences encoding these novel polypeptide chains and host cells transfected with these vectors; (4) methods of producing these polypeptide chains using recombinant DNA technology; (5) antibodies specific for these novel polypeptide chains; (6) osteogenic devices comprising these recombinantly produced proteins in association with an appropriate carrier matrix; and (7) methods of using the osteogenic devices to mimic the natural course of endochondral bone formation in mammals.

Abstract: PHPIP-120 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed, also disclosed are methods for utilizing PHPIP-120 polypeptides and polynucleotides in diagnostic assays.

Abstract: The invention described herein relates to a method for identifying antigen fragments of Toxoplasma gondii proteins, and their use as diagnostic and immunogenic agents. Said method is implemented by means of selection of DNA fragments libraries of the parasite with sera of subjects who have been infected, using the phage display technique, and is characterised in that it uses the expression/exposure vector ?KM4. The method allows also to identify antigen fragments related to the time of the infection.

Abstract: The present invention provides a method for identifying a polypeptide that interacts with a known protein, which method uses fusion proteins with GFP fragments.

Abstract: The present invention relates to novel human coagulation Factor VIIa variants having coagulant activity as well as nucleic acid constructs encoding such variants, vectors and host cells comprising and expressing the nucleic acid, pharmaceutical compositions, uses and methods of treatment.

Abstract: A method of modulating angiogenesis in a vertebrate subject, the method comprising administering to the vertebrate subject an ECRTP/DEP-1 activity-modulating amount of a composition, whereby an ECRTP/DEP-1 within the vertebrate subject is contacted by the composition; and modulating angiogenesis through the contacting of the ECRTP/DEP-1 with the composition. Optionally, the composition includes a monoclonal antibody which preferentially binds ECRTP/DEP-1. Methods for screening for modulators of ECRTP/DEP-1 are also disclosed.

Abstract: The present invention relates to phosphorylated tau protein epitopes associated with Alzheimer's disease, to protein kinases responsible for tau protein epitope phosphorylation, and to antibodies specific for the tau epitopes. Additionally, the present invention relates to pharmaceutical compositions, methods for detection, and methods of testing drugs effective in dissolving paired helical filaments associated with Alzheimer's disease.

Abstract: The present invention provides two unique monoclonal antibodies directed against a portion of the human Glycine N-methyltransferase, and methods of use for the monoclonal antibodies in detecting, monitoring and diagnosing malignancies characterized by down-regulation of expression or inappropriate expression of the Glycine N-methyltransferase.

Abstract: The present invention concerns a protein produced from an alternative splice form of the human Ghrelin gene, an obesity and/or diabetes related gene.

Abstract: An isolated nucleic acid sequence of a mitotic checkpoint gene, chfr, encodes a Chfr protein having a Forkhead-associated domain and a Ring Finger. This protein is required for regulation of the transition of cells from prophase to metaphase during mitosis. The chfr nucleic acid and Chfr polypeptide are useful in diagnosing tumorigenic cells and in screening for drugs which can inhibit the activity of Chfr in a cancer cell, thereby rendering the cell more sensitive to additional anti-tumor therapies.

Abstract: An isolated DNA of SEQ ID NO:1 is provided that encodes the transcription factor BP1, which is believed to be a repressor of the ?-globin gene. A host cell that is transformed with a vector that contains the DNA may be used to produce BP1. Vectors having a controllable promoter operably connected to the BP1 open reading frame may be used to transform ?-globin producing cells of patients with sickle cell anemia, thereby providing a treatment. Because BP1 is overexpressed in leukemia and breast cancer cells, acute myeloid leukemia, acute lymphocytic leukemia, and breast cancer can be screened for and diagnosed by determining whether BP1 is overexpressed in cell samples of patients who may have these conditions. An antisense DNA or RNA to the DNA encoding BP1 may be used as a treatment for acute myeloid leukemia, acute lymphocytic leukemia, and breast cancer.

Abstract: A method is described for generating blended nucleic acid ligands containing non-nucleic acid functional units. Specifically, a SELEX identified RNA ligand to the integrin gpIIbIIIa is conjugated to the peptide Gly-Arg-Gly-Asp-Thr-Pro (SEQ ID NO:1). This blended RNA ligand inhibits the biological activity of gpIIbIIIa with high specificity. Also described is a single-stranded DNA ligand to elastase coupled to N-methoxysuccinyl-Ala-Ala-Pro-Val-chloromethyl ketone (SEQ ID NO:2). This elastase blended nucleic acid ligand inhibits the biological activity of elastase.

Abstract: The invention provides compounds having increased or reduced immunostimulatory effect, said compounds comprising a CpG dinucleotide and an immunomodulatory moiety wherein the increased or reduced immunomodulatory effect is relative to a similar compound lacking the immunomodulatorv moiety.

Abstract: In one aspect of the invention, photoactivatable silane compounds and methods for their synthesis and use are provided. In one embodiment, the photoactivatable silane compounds synthesized are represented by a formula: PG-LS-SN, wherein PG is a photoactivatable group, LS is a linkage and spacer group, and SN is a silane group. The silanes allow the photoactivatable silane compounds to be covalently bound to the surface of a substrate such as silica. The photoactivatable group forms a hydrophobic layer that can be photochemically cross-linked with a layer of hydrophilic functional polymers. In another embodiment, a method is disclosed to synthesize a substrate of hydrophobic layers and hydrophilic functional polymer layers thereafter onto glass surfaces. An array of biopolymers such as nucleic acids and peptides may then be covalently attached to the substrate using photolithography and biopolymer synthesis.

Abstract: The present invention provides metal ion affinity peptides, fusion proteins comprising metal ion affinity peptides, and polynucleotides encoding the fusion proteins. A feature of the subject invention is that the metal ion affinity peptide has a formula selected from the group consisting of: formula 1: (His-X1-X2)n1-(His-X3-X4-X5)n2-(His-X6)n3, wherein each of X1 and X2 is independently an amino acid with an aliphatic or an amide side chain, each of X3, X4, X5 is independently an amino acid with a basic side chain (except His) or an acidic side chain, each X6 is an amino acid with an aliphatic or an amide side chain, n1 and n2 are each independently 1–3, and n3 is 1–5; formula 2: (His-Asn)n, where n=3 to 10; and formula 3: (His-X1-X2)n, wherein each of X1 and X2 is an amino acid having an acidic side chain, and n=3 to 10. The invention further provides recombinant vectors comprising subject polynucleotides, and host cells comprising the recombinant vectors.

Abstract: This invention relates to newly identified Staphylococcal polynucleotides, polypeptides encoded by such polynucleotides, the uses of such polynucleotides and polypeptides, as well as the production of such polynucleotides and polypeptides and recombinant host cells transformed with the polynucleotides. This invention also relates to inhibiting the biosynthesis or action of such polynucleotides or polypeptides and to the use of such inhibitors in therapy.

Abstract: The invention provides for lysozyme gene expression control regions which may include a 5? matrix attachment region; an intrinsically curved region of DNA; a transcription enhancer; a negative regulatory element; at least one hormone responsive element; an avian CRI repeat element; a proximal lysozyme promoter, and can be linked to a nucleotide sequence encoding a heterologous polypeptide.

Abstract: A promoter comprising any one selected from the group consisting of the nucleotide sequence of SEQ ID No: 7, the nucleotide sequence of SEQ ID No: 8, the nucleotide sequence of SEQ ID No: 9, the nucleotide sequence of SEQ ID No: 10, the nucleotide sequence of SEQ ID No: 11 and the nucleotide sequence of SEQ ID No: 12, which is capable of inducing the expression of a downstream gene of the promoter under the presence of nitrate.

Abstract: An improved delivery system for antisense oligonucleotides involves a liposomal composition, comprising a liposome which consists essentially of neutral phospholipids and an antisense oligonucleotide that is entrapped in the liposome and is selected from the group consisting of phosphodiester oligonucleotides, phosphorothioate oligonucleotides, and p-ethoxy oligonucleotides.

Abstract: Compounds, compositions and methods are provided for modulating the expression of STAT5. The compositions comprise oligonucleotides, targeted to nucleic acid encoding STAT5. Methods of using these compounds for modulation of STAT5 expression and for diagnosis and treatment of diseases and conditions associated with expression of STAT5 are provided.

Abstract: The present invention concerns methods and reagents useful in modulating vascular endothelial growth factor (VEGF, VEGF-A, VEGF-B, VEGF-C, VEGF-D) and/or vascular endothelial growth factor receptor (e.g., VEGFR1, VEGFR2 and/or VEGFr3) gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules capable of mediating RNA interference (RNAi) against VEGF and/or VEGFr gene expression and/or activity. The small nucleic acid molecules are useful in the diagnosis and treatment of cancer, proliferative diseases, and any other disease or condition that responds to modulation of VEGF and/or VEGFr expression or activity.

Abstract: Purine nucleotide derivative disodium crystals having a minimized amount of remaining alcohol such as methanol, ethanol or a mixture thereof are produced by overdrying purine nucleotide derivative disodium crystals containing the alcohol; and bringing the overdried purine nucleotide derivative disodium crystals into contact with an aqueous solution containing a hydrophilic organic solvent to control the humidity of the purine nucleotide derivative disodium crystals under a high humidity condition.

Abstract: The present invention is directed to a compound represented by the following formula (1) and to a process for producing a compound (5) from the compound (1). By use of the compound (1) of the present invention, a variety of cyclic diamine derivatives (5) or salts thereof, useful as drugs, can be produced in an industrially advantageous manner with a constant yield.